ArticleCancer immunology, immunotherapy : CII2009
Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- IFITM1 enhances anti-tumor function of unconventional TCRαβ double negative T cells by upregulating mitophagy.Science China. Life sciences · 2026Article
- SLAMF7 promotes TCRαβJournal of experimental & clinical cancer research : CR · 2025Article
- CD3+CD4-CD8- Double-Negative Lymphocytes Are Increased in the Aqueous Humor of Patients with Retinitis Pigmentosa: Their Possible Role in Mediating Inflammation.International journal of molecular sciences · 2024Article
- Targeted cancer treatment using folate-conjugated sponge-like ZIF-8 nanoparticles: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Preliminary analysis of double-negative T, double-positive T, and natural killer T-like cells in B-cell chronic lymphocytic leukemia.Cancer medicine · 2023Article
- Double-negative T cells: a promising avenue of adoptive cell therapy in transplant oncology.Journal of Zhejiang University. Science. B · 2023Article
- Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.Nature cancer · 2023Article
- Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- TCRαβ+ CD4-/CD8- "double negative" T cells in health and disease-implications for the kidney.Kidney international · 2022Review
- Review
- Application of double-negative T cells in haematological malignancies: recent progress and future directions.Biomarker research · 2022Review
- Double Negative T Regulatory Cells: An Emerging Paradigm Shift in Reproductive Immune Tolerance?Frontiers in immunology · 2022Review
- Article
- DNT Cell-based Immunotherapy: Progress and Applications.Journal of Cancer · 2020Review
- Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.Cancer discovery · 2019Article
- Reparative T lymphocytes in organ injury.The Journal of clinical investigation · 2019Review
- Elevated peripheral blood B lymphocytes and CD3Oncology letters · 2018Article
- Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.Cancer immunology, immunotherapy : CII · 2017Article
- Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.Oncoimmunology · 2016Article
- Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
The immune attack against malignant tumors require the concerted action of CD8+ cytotoxic T lymphocytes (CTL) as well as CD4+ T helper cells. The contribution of T cell receptor (TCR) alphabeta+ CD4- CD8- double-negative (DN) T cells to anti-tumor immune responses is widely unknown. In previous studies, we have demonstrated that DN T cells with a broad TCR repertoire are present in humans in the peripheral blood and the lymph nodes of healthy individuals. Here, we characterize a human DN T cell clone (T4H2) recognizing an HLA-A2-restricted melanoma-associated antigenic gp100-peptide isolated from the peripheral blood of a melanoma patient. Antigen recognition by the T4H2 DN clone resulted in specific secretion of IFN-gamma and TNF. Although lacking the CD8 molecule the gp100-specific DN T cell clone was able to confer antigen-specific cytotoxicity against gp100-loaded target cells as well as HLA-A2+ gp100 expressing melanoma cells. The cytotoxic capacity was found to be perforin/granzymeB-dependent. Together, these data indicate that functionally active antigen-specific DN T cells recognizing MHC class I-restricted tumor-associated antigen (TAA) may contribute to anti-tumor immunity in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.